{"id":5446,"date":"2026-01-08T11:33:24","date_gmt":"2026-01-08T08:33:24","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=5446"},"modified":"2026-01-08T11:33:26","modified_gmt":"2026-01-08T08:33:26","slug":"nxera-pharma-exclusive-licensing-agreement-agamree-vamorolone-santhera-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/nxera-pharma-exclusive-licensing-agreement-agamree-vamorolone-santhera-pharmaceuticals\/","title":{"rendered":"Nxera Pharma octroie des licences pour le Japon et certaines r\u00e9gions d&#039;Asie-Pacifique pour le Vamorolone de Santhera Pharmaceuticals, destin\u00e9 au traitement de la dystrophie musculaire de Duchenne."},"content":{"rendered":"<p class=\"wp-block-paragraph\">Nxera Pharma (\u201c Nxera \u201d ou \u201c la Soci\u00e9t\u00e9 \u201c ; TSE 4565) annonce avoir conclu un accord de licence exclusif avec Santhera Pharmaceuticals Holding (\u201d Santhera \u00bb) pour le d\u00e9veloppement, la fabrication et la commercialisation du vamorolone destin\u00e9 au traitement de la dystrophie musculaire de Duchenne (DMD) au Japon, en Cor\u00e9e du Sud, en Australie et en Nouvelle-Z\u00e9lande. Vamorolone est approuv\u00e9 et commercialis\u00e9 sous le nom d\u2019AGAMREE pour le traitement de la DMD, une maladie neurod\u00e9g\u00e9n\u00e9rative h\u00e9r\u00e9ditaire rare, aux \u00c9tats-Unis, dans l\u2019Union europ\u00e9enne, au Royaume-Uni et en Chine.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Apprendre encore plus<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/fr\/what-is-agamree-vamorolone-what-is-agamree-used-for\/\" target=\"_blank\" rel=\"noreferrer noopener\">Qu&#039;est-ce que l&#039;Agamree (vamorolone) ? \u00c0 quoi sert l&#039;Agamree ?<\/a><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Le Vamorolone est approuv\u00e9 et commercialis\u00e9 sous le nom d&#039;AGAMREE pour le traitement de la dystrophie musculaire de Duchenne (DMD) aux \u00c9tats-Unis, dans l&#039;Union europ\u00e9enne, au Royaume-Uni et en Chine.<\/strong><\/li>\n\n\n\n<li>De nouvelles donn\u00e9es sur cinq ans concernant le vamorolone ont mis en \u00e9vidence un profil de s\u00e9curit\u00e9 nettement am\u00e9lior\u00e9, avec une r\u00e9duction des fractures vert\u00e9brales, une incidence plus faible de cataractes et le maintien d&#039;une croissance normale. Les effets ind\u00e9sirables constituant une limitation majeure des corticost\u00e9ro\u00efdes conventionnels, le profil de s\u00e9curit\u00e9 du vamorolone, associ\u00e9 \u00e0 son efficacit\u00e9 comparable, pourrait potentiellement remplacer les traitements st\u00e9ro\u00efdiens actuels.<\/li>\n\n\n\n<li><strong>Cette transaction permet \u00e0 Nxera de poursuivre sa mission d&#039;offrir des m\u00e9dicaments innovants aux patients du Japon et de la r\u00e9gion Asie-Pacifique, conform\u00e9ment \u00e0 sa vision 2030 de devenir une entreprise biopharmaceutique japonaise \u00e0 forte croissance et tr\u00e8s rentable.<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>En savoir plus<\/strong>:&nbsp;<a href=\"https:\/\/dmdwarrior.com\/fr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Essais cliniques sur la dystrophie musculaire de Duchenne (Liste de toutes les recherches)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Nxera Pharma (\u201cNxera\u201d or \u201cthe Company; TSE 4565) announces that it has entered an exclusive licensing agreement for the development, manufacturing and commercialization of vamorolone for the treatment of Duchenne Muscular Dystrophy (DMD) in Japan, South Korea, Australia and New Zealand with Santhera Pharmaceuticals Holding (\u201cSanthera\u201d) Vamorolone is approved and marketed as AGAMREE for the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5447,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[42,142,474,41,43],"class_list":["post-5446","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-agamree","tag-japan","tag-nxera-pharma","tag-santhera","tag-vamorolone"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/5446","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=5446"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/5446\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/5447"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=5446"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=5446"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=5446"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}